Advanced Search

Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2015 February;63(1) > Minerva Cardioangiologica 2015 February;63(1):11-20

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEMINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases

Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752

Frequency: Bi-Monthly

ISSN 0026-4725

Online ISSN 1827-1618

 

Minerva Cardioangiologica 2015 February;63(1):11-20

    ORIGINAL ARTICLES

The TITAN-AMI multicenter registry evaluating the usage of Titan2 stent in patients with ST segment elevation myocardial infarction. Final result at 12-month follow-up

Gómez-Hospital J. A. 1, Mauri J. 2, Pinar E. 3, Goicolea J. 4, García Del Blanco B. 5, Serra A. 6, Tizon-Marcos H. 7, Molina E. 8, Sanchez E. 9, Aragón V. 10, Masotti M. 11, Rodríguez J. 12, Jiménez J. 13, Ortas R. 14, Martínez P. 15, Serra B. 16, Moreu J. 17, Diego Nieto G. 18, Bossa F. 19, Nogales J. M. 20, Bassaganyas J. 21, Díaz J. 22, Cascón J. D. 23

1 Department of Cardiology, Hospital Universitari Bellvitge, Barcelona, Spain;
2 Department of Cardiology, Hospital Germans Tries i Pujol, Badalona, Barcelona, Spain;
3 Department of Cardiology, Hospital Virgen de la Arrixaca, Murcia, Spain;
4 Department of Cardiology, Hospital Puerta de Hierro Majadahonda, Madrid, Spain;
5 Department of Cardiology, Hospital Vall d’Hebrón, Barcelona, Spain;
6 Department of Cardiology, Hospital Sant Pau, Barcelona, Spain;
7 Department of Cardiology, Hospital del Mar, Barcelona, Spain;
8 Department of Cardiology, Hospital Virgen de las Nieves, Granada, Spain;
9 Department of Cardiology, Hospital Universitari La Fe de Valencia, Valencia, Spain;
10 Department of Cardiology, Complejo Hospitalario de Jaen, Jaen, Spain;
11 Department of Cardiology, Hospital Clinic Barcelona, Barcelona, Spain;
12 Department of Cardiology, Hospital Universitario de Salamanca, Salamanca, Spain;
13 Department of Cardiology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain;
14 Department of Cardiology, Hospital Arnau de Vilanova, Lleida, Spain;
15 Department of Cardiology, Hospital Puerto Real, Cádiz, Spain;
16 Department of Cardiology, Mútua de Terrassa, Barcelona, Spain;
17 Departmentof Cardiology, Hospital Virgen de la Salud, Toledo, Spain;
18 Departmentof Cardiology, Hospital de la Princesa, Madrid, Spain;
19 Departmentof Cardiology, Hospital Universitario de Canarias, Tenerife, Spain;
20 Departmentof Cardiology, Hospital Infanta Cristina, Badajoz, Spain;
21 Departmentof Cardiology, Hospital Josep Trueta, Girona, Spain;
22 Departmentof Cardiology, Hospital Juan Ramon Jiménez, Huelva, Spain;
23 Departmentof Cardiology, Hospital General Universitario Santa Lucía, Cartagena, Spain

AIM: Primary percutaneous coronary intervention with stent implantation is the recommended treatment for patients with ST elevation myocardial infarction (STEMI). Data from randomised trials showed good performance by a titanium-nitric-oxide coated stent in this context. The aim of this study was to confirm these data.
METHODS: A multicentre registry was compiled in 23 hospitals in Spain in an all-comers population. We selected patients with STEMI from a global Titan AMI registry that included patients with acute coronary syndrome. Primary endpoint was the composite of cardiac death, non-fatal myocardial infarction, stent thrombosis and target lesion revascularisation, at 12-month follow-up.
RESULTS: The study included 893 patients with STEMI. We included all possibilities for PCI: 86.6% primary, 5% facilitated after successful fibrinolysis and 8.4% rescue PCI after failed fibrinolysis. The primary endpoint was reached in 8.4% of the patients: cardiac death 2.7%, reinfarction 3.4%, target lesion revascularisation 3.5% and definite or probable stent thrombosis 2.8%. The majority of stent thromboses presented in the first 30 days after PCI.
CONCLUSION: A bioactive stent (titanium-nitric-oxide coated stent) is a possible alternative for the treatment of patients with STEMI. One-year follow-up showed better results than those presented by a regular bare-metal stent or first-generation drug-eluting stent in terms of stent thrombosis.

language: English


FULL TEXT  REPRINTS

top of page